
RPRX
Royalty Pharma plc
$35.98
+$0.36(+1.01%)
81
Overall
100
Value
63
Tech
--
Quality
Market Cap
$20.98B
Volume
2.99M
52W Range
$24.05 - $38.00
Target Price
$44.33
Order:
Income Statement
Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|
REVENUE | |||||||
Total Revenue | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | ||
Total Revenue | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | ||
GROSS PROFIT | |||||||
Gross Profit | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | ||
OPERATING EXPENSES | |||||||
Operating Expenses | $296.1M | $405.9M | $1.3B | $301.7M | $238.7M | ||
Research & Development | $26.3M | $200.1M | $177.1M | $52.0M | $2.0M | ||
Research Expense | $26.3M | $200.1M | $177.1M | $52.0M | $2.0M | ||
Selling, General & Administrative | $181.7M | $182.8M | $227.3M | $249.7M | $236.7M | ||
General & Administrative Expenses | $181.7M | $182.8M | $227.3M | $249.7M | $236.7M | ||
Salaries & Wages | $5.4M | $2.4M | $2.2M | $2.4M | $2.3M | ||
Depreciation & Amortization | $23.1M | $23.0M | $5.7M | -- | -- | ||
Depreciation & Amortization | $23.1M | $23.0M | $5.7M | -- | -- | ||
Amortization | $23.1M | $23.0M | $5.7M | $20.5M | $19.6M | ||
Other Operating Expenses | $65.1M | -- | -- | -- | -- | ||
OPERATING INCOME | |||||||
Operating income | $1.6B | $1.4B | $307.1M | $1.5B | $1.3B | ||
EBITDA | $1.9B | $1.4B | $418.0M | $1.7B | $1.3B | ||
NON-OPERATING ITEMS | |||||||
Interest Expense (Non-Operating) | $157.1M | $166.1M | $188.0M | $187.2M | -- | ||
Intinc | -- | -- | -- | $72.3M | $47.3M | ||
Net Non-Operating Interest Income/Expense | $-157.1M | $-619.0M | $109.6M | $-488.4M | $-685.1M | ||
Gain on Sale of Securities | $-13.7M | $32.0M | $174.9M | $-2.3M | $-6.0M | ||
Other Income/Expense | $-263.6M | $23.4M | $-583.2M | $-322.8M | $-216.5M | ||
Other Special Charges | $-32.8M | $-5.7M | $-14.8M | $-21.7M | $-1.5M | ||
SPECIAL ITEMS | |||||||
Special Income Charges | $-74.7M | $-4.5M | $-615.8M | $-20.9M | $-1.1M | ||
Impairment of Capital Assets | $65.1M | -- | $615.8M | -- | -- | ||
PRE-TAX INCOME | |||||||
EBIT | $1.9B | $1.4B | $418.0M | $1.7B | $1.3B | ||
Pre-Tax Income | $1.7B | $1.2B | $230.1M | $1.7B | $1.3B | ||
NET INCOME | |||||||
Net Income | $975.0M | $619.7M | $42.8M | $1.1B | $859.0M | ||
Net Income (Continuing Operations) | $975.0M | $619.7M | $230.1M | $1.7B | $1.3B | ||
Net Income (Discontinued Operations) | $975.0M | $619.7M | $42.8M | $1.1B | $859.0M | ||
Net Income (Common Stockholders) | $495.2M | $619.7M | $42.8M | $1.1B | $859.0M | ||
Normalized Income | $1.4B | -- | -- | -- | $1.3B | ||
TOTALS | |||||||
Total Expenses | $296.1M | $405.9M | $1.3B | $301.7M | $238.7M | ||
SHARE & EPS DATA | |||||||
Average Shares Outstanding | $375.4M | $414.8M | $438.0M | $447.6M | $448.2M | ||
Average Shares Outstanding (Diluted) | $375.5M | $414.8M | $438.0M | $602.9M | $594.1M | ||
Shares Outstanding | $607.1M | $607.2M | $607.2M | $597.4M | $576.5M | ||
Basic EPS | $1.32 | $1.49 | $0.10 | $2.54 | $1.92 | ||
Basic EPS (Continuing Operations) | $1.32 | $1.49 | $0.10 | $2.54 | $1.92 | ||
Diluted EPS | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | ||
Diluted EPS (Continuing Operations) | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | ||
Dividend Per Share | $0.60 | $0.68 | $0.76 | $0.80 | $0.84 | ||
OTHER METRICS | |||||||
Earnings from equity interest | $44.5M | $-19.5M | $-9.0M | $28.9M | $29.6M | ||
Earnings From Equity Interest Net Of Tax | $44.5M | $-19.5M | $-9.0M | $28.9M | $29.6M | ||
Minority Interests | $-726.9M | $-621.5M | $-187.2M | $-565.3M | $-471.8M | ||
Net Income Discontinuous Operations | $-230.8M | $-452.8M | -- | -- | -- | ||
Other Gand A | $181.7M | $182.8M | $227.3M | $249.7M | $236.7M | ||
Provision For Gain Loss On Disposal | $-230.8M | $-452.8M | -- | -- | -- | ||
Othspecchg | $9.6M | $4.5M | $11.1M | $20.9M | $1.1M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | RPRX | $35.98 | +1.0% | 2.99M |
3 | ||||
4 | ||||
5 | ||||
6 |